+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Burns - Pipeline Review, H2 2019

  • ID: 4866567
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 99 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aegle Therapeutics Corp
  • Anterogen Co Ltd
  • Destiny Pharma Plc
  • Hypo-Stream Ltd
  • MediWound Ltd
  • Phagelux Inc
  • MORE
Burns - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Burns - Pipeline Review, H2 2019, provides an overview of the Burns (Dermatology) pipeline landscape.

A burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Burns - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 4, 2, 17, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Burns (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aegle Therapeutics Corp
  • Anterogen Co Ltd
  • Destiny Pharma Plc
  • Hypo-Stream Ltd
  • MediWound Ltd
  • Phagelux Inc
  • MORE
Introduction
Report Coverage
Burns - Overview
Burns - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Burns - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Burns - Companies Involved in Therapeutics Development
Aegle Therapeutics Corp
AlgiPharma AS
Alliance Pharma Plc
Amarantus Bioscience Holdings Inc
Anterogen Co Ltd
Bioharmony Therapeutics Inc
Biomendics LLC
CFM Pharma Holding BV
Destiny Pharma Plc
Energenesis Biomedical Co Ltd
FortuneRock (China) Ltd
GNT Pharma Co Ltd
Hunan Sanqing Pharmaceutical Co Ltd
Hypo-Stream Ltd
Madam Therapeutics BV
Mallinckrodt Plc
MediWound Ltd
MicroCures Inc
NeoMatrix Therapeutics Inc
Novion Technologies Inc
Phagelux Inc
Riptide Bioscience Inc
Roji Ltd
Se-cure Pharmaceuticals Ltd
Shulov Innovative Science Ltd
Stemsynergy Therapeutics Inc
TGV-Inhalonix Inc
Theragnostic Technologies Inc
TreeFrog Therapeutics SAS
USV Pvt Ltd
viDA Therapeutics Inc
Washburn Therapeutics Inc
Burns - Drug Profiles
(cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGLE-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aspoxicillin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BH-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Burns and Bone Fractures - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bromelains - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Dermatology and Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENERGIF-711 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epidermal growth factor biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISN-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mul-1867 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neu-2000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligomer G for Burn Wounds - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-01SS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Activate FGFR for Cardiovascular, CNS, Dermatology and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pyrvinium pamoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize EPCR for Wounds and Burns - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RNAi Gene therapy to Inhibit FL2 for Erectile Dysfunction, Burns and Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAAP-148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFR-9X0125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
silver sulfadiazine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Burns - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium hypochlorite - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Burns and Dermatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tolasure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vanadis-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTI-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XF-70 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Burns - Dormant Projects
Burns - Discontinued Products
Burns - Product Development Milestones
Featured News & Press Releases
Oct 02, 2019: Vericel and MediWound Announce Initiation of U.S. NexoBrid Expanded Access Treatment Protocol
Sep 24, 2019: Mallinckrodt reports positive burn treatment results
Sep 03, 2019: NexoBrid Highlighted in 39 presentations at the 18th European Burns Association Congress in Helsinki
Jun 04, 2019: NexoBrid receives Marketing Authorization from Peru’s Ministry of Health
May 29, 2019: BARDA upsizes support for NexoBrid with an additional $21 million to fund continuous access treatment protocol for thermal burn
Apr 24, 2019: Mallinckrodt Completes Expansion of Operations and Manufacturing Facility for StrataGraft Regenerative Skin Tissue in Madison, Wis.
Jan 23, 2019: MediWound reports positive top-line data from NexoBrid study
Oct 15, 2018: Mallinckrodts Stratatech company awarded $26 million in additional BARDA funding for pediatric studies of stratagraft skin tissue in thermal burns
Sep 24, 2018: MediWound awarded additional BARDA contract valued Up to $43 Million for development of NexoBrid for sulfur mustard injuries
Sep 05, 2018: NexoBrid receives marketing authorization from Russia's Ministry of Health
Jul 18, 2018: U.S. FDA designates Mallinckrodt's StrataGraft as regenerative medicine advanced therapy
Jun 19, 2018: MediWound Expands Its NexoBrid Phase 3 Children Innovation Debridement Study (CIDS) to the U.S.
Jun 11, 2018: MediWound Completes Enrollment in NexoBrid U.S. Phase 3 DETECT Study
Jun 04, 2018: NexoBrid Receives Marketing Authorization From South Koreas Ministry of Health
Apr 09, 2018: MediWound’s NexoBrid to be Highlighted in Presentations at the American Burn Association 50th Annual Meeting Being Held on April 10-13, 2018 in Chicago
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Burns, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Universities/Institutes, H2 2019
Table 5: Products under Development by Companies, H2 2019
Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 7: Products under Development by Universities/Institutes, H2 2019
Table 8: Number of Products by Stage and Target, H2 2019
Table 9: Number of Products by Stage and Mechanism of Action, H2 2019
Table 10: Number of Products by Stage and Route of Administration, H2 2019
Table 11: Number of Products by Stage and Molecule Type, H2 2019
Table 12: Burns - Pipeline by Aegle Therapeutics Corp, H2 2019
Table 13: Burns - Pipeline by AlgiPharma AS, H2 2019
Table 14: Burns - Pipeline by Alliance Pharma Plc, H2 2019
Table 15: Burns - Pipeline by Amarantus Bioscience Holdings Inc, H2 2019
Table 16: Burns - Pipeline by Anterogen Co Ltd, H2 2019
Table 17: Burns - Pipeline by Bioharmony Therapeutics Inc, H2 2019
Table 18: Burns - Pipeline by Biomendics LLC, H2 2019
Table 19: Burns - Pipeline by CFM Pharma Holding BV, H2 2019
Table 20: Burns - Pipeline by Destiny Pharma Plc, H2 2019
Table 21: Burns - Pipeline by Energenesis Biomedical Co Ltd, H2 2019
Table 22: Burns - Pipeline by FortuneRock (China) Ltd, H2 2019
Table 23: Burns - Pipeline by GNT Pharma Co Ltd, H2 2019
Table 24: Burns - Pipeline by Hunan Sanqing Pharmaceutical Co Ltd, H2 2019
Table 25: Burns - Pipeline by Hypo-Stream Ltd, H2 2019
Table 26: Burns - Pipeline by Madam Therapeutics BV, H2 2019
Table 27: Burns - Pipeline by Mallinckrodt Plc, H2 2019
Table 28: Burns - Pipeline by MediWound Ltd, H2 2019
Table 29: Burns - Pipeline by MicroCures Inc, H2 2019
Table 30: Burns - Pipeline by NeoMatrix Therapeutics Inc, H2 2019
Table 31: Burns - Pipeline by Novion Technologies Inc, H2 2019
Table 32: Burns - Pipeline by Phagelux Inc, H2 2019
Table 33: Burns - Pipeline by Riptide Bioscience Inc, H2 2019
Table 34: Burns - Pipeline by Roji Ltd, H2 2019
Table 35: Burns - Pipeline by Se-cure Pharmaceuticals Ltd, H2 2019
Table 36: Burns - Pipeline by Shulov Innovative Science Ltd, H2 2019
Table 37: Burns - Pipeline by Stemsynergy Therapeutics Inc, H2 2019
Table 38: Burns - Pipeline by TGV-Inhalonix Inc, H2 2019
Table 39: Burns - Pipeline by Theragnostic Technologies Inc, H2 2019
Table 40: Burns - Pipeline by TreeFrog Therapeutics SAS, H2 2019
Table 41: Burns - Pipeline by USV Pvt Ltd, H2 2019
Table 42: Burns - Pipeline by viDA Therapeutics Inc, H2 2019
Table 43: Burns - Pipeline by Washburn Therapeutics Inc, H2 2019
Table 44: Burns - Dormant Projects, H2 2019
Table 45: Burns - Dormant Projects, H2 2019 (Contd..1), H2 2019
Table 46: Burns - Dormant Projects, H2 2019 (Contd..2), H2 2019
Table 47: Burns - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Burns, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Top 10 Targets, H2 2019
Figure 4: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 5: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Routes of Administration, H2 2019
Figure 8: Number of Products by Stage and Routes of Administration, H2 2019
Figure 9: Number of Products by Top 10 Molecule Types, H2 2019
Figure 10: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aegle Therapeutics Corp
  • AlgiPharma AS
  • Alliance Pharma Plc
  • Amarantus Bioscience Holdings Inc
  • Anterogen Co Ltd
  • Bioharmony Therapeutics Inc
  • Biomendics LLC
  • CFM Pharma Holding BV
  • Destiny Pharma Plc
  • Energenesis Biomedical Co Ltd
  • FortuneRock (China) Ltd
  • GNT Pharma Co Ltd
  • Hunan Sanqing Pharmaceutical Co Ltd
  • Hypo-Stream Ltd
  • Madam Therapeutics BV
  • Mallinckrodt Plc
  • MediWound Ltd
  • MicroCures Inc
  • NeoMatrix Therapeutics Inc
  • Novion Technologies Inc
  • Phagelux Inc
  • Riptide Bioscience Inc
  • Roji Ltd
  • Se-cure Pharmaceuticals Ltd
  • Shulov Innovative Science Ltd
  • Stemsynergy Therapeutics Inc
  • TGV-Inhalonix Inc
  • Theragnostic Technologies Inc
  • TreeFrog Therapeutics SAS
  • USV Pvt Ltd
  • viDA Therapeutics Inc
  • Washburn Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll